{"drugs":["Arcalyst","Rilonacept"],"mono":{"0":{"id":"928999-s-0","title":"Generic Names","mono":"Rilonacept"},"1":{"id":"928999-s-1","title":"Dosing and Indications","sub":[{"id":"928999-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Cryopyrin associated periodic syndrome:<\/b> loading dose, 320 mg SUBQ (160 mg at 2 different sites); then 160 mg SUBQ once weekly<\/li><li><b>Gouty arthritis, acute, During initiation of urate-lowering therapy; Prophylaxis:<\/b> 160 mg SUBQ loading dose followed by 80 mg SUBQ once weekly for 16 weeks  OR 320 mg SUBQ loading dose followed by 160 mg SUBQ once weekly for 16 weeks have been used in clinical studies<\/li><\/ul>"},{"id":"928999-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in children younger than 12 years<\/li><li><b>Cryopyrin associated periodic syndrome:<\/b> (12 to 17 years of age) loading dose, 4.4 mg\/kg SUBQ (MAX of 320 mg) as 1 or 2 injections with a MAX volume of 2 mL (if administered as 2 injections, then administer at 2 different sites); then 2.2 mg\/kg (MAX 160 mg) SUBQ once weekly<\/li><\/ul>"},{"id":"928999-s-1-6","title":"Dose Adjustments","mono":"<b>geriatric:<\/b> no dosage adjustment is required "},{"id":"928999-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Cryopyrin associated periodic syndrome<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Gouty arthritis, acute, During initiation of urate-lowering therapy; Prophylaxis<br\/>"}]},"3":{"id":"928999-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928999-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"928999-s-3-10","title":"Precautions","mono":"<ul><li>concurrent use of live vaccines or tumor necrosis factor (TNF) inhibitors is not recommended<\/li><li>infections, chronic or active; potential for exacerbation; discontinue if serious infection develops<\/li><li>hypersensitivity reactions have occurred<\/li><li>latent tuberculosis should be treated prior to initiating therapy<\/li><\/ul>"},{"id":"928999-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928999-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928999-s-4","title":"Drug Interactions","sub":{"1":{"id":"928999-s-4-14","title":"Major","mono":"<ul><li>Adalimumab (theoretical)<\/li><li>Adenovirus Vaccine Type 4, Live (theoretical)<\/li><li>Adenovirus Vaccine Type 7, Live (theoretical)<\/li><li>Anakinra (theoretical)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (theoretical)<\/li><li>Etanercept (theoretical)<\/li><li>Infliximab (theoretical)<\/li><li>Influenza Virus Vaccine, Live (theoretical)<\/li><li>Measles Virus Vaccine, Live (theoretical)<\/li><li>Mumps Virus Vaccine, Live (theoretical)<\/li><li>Poliovirus Vaccine, Live (theoretical)<\/li><li>Rotavirus Vaccine, Live (theoretical)<\/li><li>Rubella Virus Vaccine, Live (theoretical)<\/li><li>Smallpox Vaccine (theoretical)<\/li><li>Typhoid Vaccine (theoretical)<\/li><li>Varicella Virus Vaccine (theoretical)<\/li><li>Yellow Fever Vaccine (theoretical)<\/li><\/ul>"}}},"5":{"id":"928999-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (48%)<\/li><li><b>Immunologic:<\/b>Infectious disease (18% to 48%)<\/li><li><b>Respiratory:<\/b>Upper respiratory infection (26%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage<\/li><li><b>Hematologic:<\/b>Neutropenia<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (rare)<\/li><li><b>Neurologic:<\/b>Meningitis<\/li><\/ul>"},"6":{"id":"928999-s-6","title":"Drug Name Info","sub":{"0":{"id":"928999-s-6-17","title":"US Trade Names","mono":"Arcalyst<br\/>"},"2":{"id":"928999-s-6-19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Interleukin-1 Inhibitor<\/li><\/ul>"},"3":{"id":"928999-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928999-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928999-s-7","title":"Mechanism Of Action","mono":"Rilonacept is a targeted inhibitor of interleukin-1 (IL-1), the key driver of inflammation in cryopyrin-associated periodic syndromes (CAPS). Rilonacept acts as a decoy receptor that binds IL-1 beta and the blocks IL-1 beta signaling, thereby preventing its interaction with cell surface receptors. It also binds IL-1 alpha and IL-1 receptor antagonist with reduced affinity.<br\/>"},"9":{"id":"928999-s-9","title":"Administration","mono":"<b>Injection, subcutaneous<\/b><br\/><ul><li>reconstitute with 2.3 mL of preservative-free sterile water and shake vial for 1 minute and then allow vial to sit for 1 minute; this results in 80-mg\/mL solution<\/li><li>after reconstitution, keep at room temperature, protect from light, and use within 3 hours<\/li><li>withdraw the required volume with a new 27-gauge, 0.5-inch needle<\/li><li>rotate appropriate injection sites, such as the abdomen, thigh, or upper arm; never inject at bruised, red, tender, or hard sites<\/li><\/ul>"},"10":{"id":"928999-s-10","title":"Monitoring","mono":"<ul><li>clinical improvement of cryopyrin-associated periodic syndromes (CAPS), such as fever, urticaria-like rash, arthralgia, myalgia, fatigue, conjunctivitis, and other common features<\/li><li>signs of serious infection or potential exacerbation of chronic or active infections, such as a fever, cough, flu-like symptoms, or open sores on the body<\/li><li>hypersensitivity or injection-site reactions<\/li><li>lipid profiles; 2 to 3 months after initiation of therapy and periodically<\/li><li>potential reduced immune response to new antigens if vaccination is given during rilonacept therapy<\/li><li>potential use of concomitant medications that block interleukin-1 (IL-1) or tumor necrosis factor (TNF)<\/li><\/ul>"},"11":{"id":"928999-s-11","title":"How Supplied","mono":"<b>Arcalyst<\/b><br\/>Subcutaneous Powder for Solution: 220 MG<br\/>"},"13":{"id":"928999-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid vaccines unless approved by healthcare professional.<\/li><li>This drug may cause sinusitis, cough, or hypoesthesia.<\/li><li>Instruct patient to report any persistent injection-site reaction (including pain, inflammation, edema, urticaria, warmth, and hemorrhage).<\/li><li>Instruct patient to report signs\/symptoms of infection (fever, cough, flu-like symptoms, or open sores).<\/li><li>Teach patient proper technique and placement of injections.<\/li><li>Instruct patient to inject the missed dose as soon as they remember, up until the day before the next scheduled dose, then take the next dose at the regularly scheduled time.<\/li><\/ul>"}}}